Kalif Eliyahu Sharon 4

What Happened

• Kalif Eliyahu Sharon, Chief Financial Officer of Teva Pharmaceutical Industries Ltd. (TEVA), reported the conversion/exercise of 19,916 derivative instruments (restricted share units) into ordinary shares on March 5, 2026. The filing also shows a corresponding disposition of 19,916 derivative shares at a reported price of $0.00. No cash sale proceeds are reported in this filing.

Key Details

• Transaction date: March 5, 2026. Form 4 filed: March 9, 2026 (timely by SEC reporting rules).
• Reported items: one acquisition/conversion of 19,916 shares (price N/A) and one disposition of 19,916 shares at $0.00 (transaction code M — exercise/conversion of a derivative).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Relevant footnotes:
  • F1: Ordinary Shares may be represented by American Depositary Shares (ADS), each currently representing one Ordinary Share.
  • F2: Each restricted share unit (RSU) represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one share.
  • F3: These RSUs were granted on March 5, 2025; 19,916 vested on March 5, 2026 (additional tranches vest in subsequent years).
• No open-market sale or purchase proceeds are reported; the filing does not state any 10b5-1 plan or tax-withholding details.

Context

• The filing reflects RSU vesting/settlement rather than an open-market purchase or sale. F3 confirms these were RSUs granted on March 5, 2025 with the 19,916-unit tranche vesting on March 5, 2026.
• Because RSUs can be settled in either shares or cash (per F2), this Form 4 shows conversion activity but does not indicate a cash sale or reveal the insider’s market sentiment.